These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9671385)

  • 1. A potential risk of sublingual nifedipine treatment in surgically treated patients in Japan.
    Kobayashi E; Kitoh Y; Fujimura A
    Crit Care Med; 1998 Jul; 26(7):1293. PubMed ID: 9671385
    [No Abstract]   [Full Text] [Related]  

  • 2. Sublingual nifedipine in elderly patients: even a low dose induces myocardial ischaemia.
    Ishibashi Y; Shimada T; Yoshitomi H; Sano K; Oyake N; Umeno T; Sakane T; Murakami Y; Morioka S
    Clin Exp Pharmacol Physiol; 1999; 26(5-6):404-10. PubMed ID: 10386229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of sublingual nifedipine: a continuing concern.
    Messerli FH; Grossman E
    Arch Intern Med; 1999 Oct; 159(19):2259-60. PubMed ID: 10547164
    [No Abstract]   [Full Text] [Related]  

  • 4. [A 73-year-old patient with hypertensive crisis. Was the use of calcium antagonist nifedipine justified?].
    Wenzel UO; Pfalzer B; Meinertz T; Stahl RA
    Internist (Berl); 1999 Feb; 40(2):205-9. PubMed ID: 10097979
    [No Abstract]   [Full Text] [Related]  

  • 5. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension.
    Peters FP; de Zwaan C; Kho L
    Arch Intern Med; 1997 Dec 8-22; 157(22):2665-6. PubMed ID: 9531240
    [No Abstract]   [Full Text] [Related]  

  • 6. Nifedipine in patients with heart disease.
    Phillips RA; Krakoff LR
    Circulation; 1996 Apr; 93(7):1474-5. PubMed ID: 8641043
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcium-channel blockers: an increasing cause of pulmonary edema during tocolytic therapy.
    Gatault P; Genee O; Legras A; Garot D; Mercier E; Fichet J
    Int J Cardiol; 2008 Nov; 130(3):e123-4. PubMed ID: 17900721
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical features and up-to-date therapy of hypertensive emergencies].
    Meyer FP
    Dtsch Med Wochenschr; 2004 Apr; 129(14):768; author reply 768-9. PubMed ID: 15042498
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards.
    Marwick C
    JAMA; 1996 Feb; 275(6):423-4. PubMed ID: 8627948
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a slow-release nifedipine on 24-hour ambulatory blood pressure and ischemic changes on 24-hour ambulatory electrocardiogram in patients with severe coronary artery disease.
    Matsumoto N; Ideishi M; Sasaguri M; Nii T; Nakashima Y; Arakawa K
    Cardiology; 2000; 94(1):36-43. PubMed ID: 11111143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?
    Grossman E; Messerli FH; Grodzicki T; Kowey P
    JAMA; 1996 Oct 23-30; 276(16):1328-31. PubMed ID: 8861992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nifedipine in ischemic heart disease: a ban on its use or a differential approach to therapy?].
    Martsevich SIu
    Ter Arkh; 1996; 68(9):31-5. PubMed ID: 9005608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channel antagonists: morbidity and mortality--what's the evidence?
    Straka RJ; Swanson AL; Parra D
    Am Fam Physician; 1998 Apr; 57(7):1551-60. PubMed ID: 9556644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
    Furberg CD; Psaty BM; Meyer JV
    Circulation; 1995 Sep; 92(5):1326-31. PubMed ID: 7648682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nifedipine trials.
    Rafflenbeul W
    Circulation; 1996 Apr; 93(7):1473-4. PubMed ID: 8641042
    [No Abstract]   [Full Text] [Related]  

  • 16. Non-substitution of nifedipine slow-release preparations.
    Van Veenhuyzen D; Coetzee R
    S Afr Med J; 2002 Nov; 92(11):838, 840. PubMed ID: 12506575
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA committee recommends stronger warnings against inappropriate use of immediate-release nifedipine.
    Miller JL
    Am J Health Syst Pharm; 1996 Mar; 53(6):599-600. PubMed ID: 8800958
    [No Abstract]   [Full Text] [Related]  

  • 18. Nifedipine-induced gingival overgrowth.
    Johnson RB
    Ann Pharmacother; 1997; 31(7-8):935. PubMed ID: 9220065
    [No Abstract]   [Full Text] [Related]  

  • 19. Risks and benefits of calcium antagonists.
    Opie LH
    Lancet; 1995 Oct; 346(8980):961. PubMed ID: 7564738
    [No Abstract]   [Full Text] [Related]  

  • 20. Another report of adverse reactions to immediate-release nifedipine.
    Fami MJ; Ho NT; Mason CM
    Pharmacotherapy; 1998; 18(5):1133-5. PubMed ID: 9758326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.